PMID- 32104076 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220413 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Comparison of chemoembolization with CalliSpheres((R)) microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. PG - 941-956 LID - 10.2147/CMAR.S187203 [doi] AB - PURPOSE: This study aimed to compare the efficacy and safety between transarterial chemoembolization (TACE) with CalliSpheres((R)) microspheres (CSM-TACE) and conventional TACE (cTACE) in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Three hundred and thirty-five HCC patients receiving CSM-TACE or cTACE were consecutively enrolled in this multi-center, retrospective cohort study, and then divided into CSM-TACE group and cTACE group accordingly. Complete response (CR), objective response (ORR) and disease control response (DCR) was assessed according to mRECIST criteria at 1 month (M1), 3 months(M3) and 6 months(M6) after treatment. Progression-free survival (PFS) and overall survival (OS) were assessed. Liver function indexes and adverse events (AEs) were also evaluated. RESULTS: CR at M3 (P=0.020) and ORR at M1 (P<0.001), M3 (P<0.001) and M6 (P=0.017) after treatment were significantly higher in the CSM-TACE compared with cTACE group. DCRs, PFS (25.3 months vs 24.2 months, P=0.503) and OS (27.8 months vs 25.3 months, P=0.203) were similar between the two groups. CSM-TACE was independently correlated with higher ORR at M1 (P=0.002) and longer OS (P=0.023). Abnormal alkaline phosphatase (ALP) (P=0.049) was independently associated with lower ORR at M3, and history of alcohol intake (P=0.019) and largest nodule size >/=7 cm (P=0.015) independently correlated with lower ORR at M6 (P=0.015). Largest nodule size >/=7 cm (P=0.029) and abnormal albumin (ALB) (P=0.046) were independently associated with shorter PFS. Child-Pugh stage B/C (P=0.023), abnormal ALB (P=0.001), ALP (P=0.008) and alpha-fetoprotein (AFP) (P=0.005) were independently associated with shorter OS. Most liver function indexes and AEs were similar between the two groups (P>0.05), except that ALP (P=0.005), total bilirubin (P=0.031), pain during procedure (P=0.034) and occurrence of fever post(treatment (P=0.017) were significantly elevated in the CSM-TACE compared with cTACE group. CONCLUSION: CSM-TACE presents with a better treatment response and similar survival profile compared with cTACE in HCC patients. CI - (c) 2020 Liang et al. FAU - Liang, Bin AU - Liang B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. FAU - Xiang, Hua AU - Xiang H AD - Department of Interventional Radiology, Hunan Provincial People's Hospital, Changsha, People's Republic of China. FAU - Ma, Cong AU - Ma C AD - Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China. FAU - Xiong, Bin AU - Xiong B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. FAU - Ma, Yilong AU - Ma Y AD - Department of Interventional Radiology, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, People's Republic of China. FAU - Zhao, Chang AU - Zhao C AD - Department of Interventional Radiology, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, People's Republic of China. FAU - Yao, Yuanhui AU - Yao Y AD - Department of Interventional Radiology, Hunan Provincial People's Hospital, Changsha, People's Republic of China. FAU - Zhang, Zishu AU - Zhang Z AD - Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China. FAU - Chen, Changyong AU - Chen C AD - Department of Radiology, Xiangya Hospital General South University, Changsha, People's Republic of China. FAU - Li, Haiping AU - Li H AD - Department of Radiology, Xiangya Hospital General South University, Changsha, People's Republic of China. FAU - Long, Qingyun AU - Long Q AD - Department of Interventional Radiology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Zhou, Jun AU - Zhou J AD - Department of Interventional Radiology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China. FAU - Luo, Chao AU - Luo C AD - Department of Radiology, Wuhan General Hospital of Guangzhou Military Region, Wuhan, People's Republic of China. FAU - Qiu, Huaiming AU - Qiu H AD - Department of Radiology, Wuhan General Hospital of Guangzhou Military Region, Wuhan, People's Republic of China. FAU - Hu, Hongyao AU - Hu H AD - Department of Interventional Radiology, Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, People's Republic of China. FAU - Zhao, Hui AU - Zhao H AD - Department of Interventional Radiology, Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, People's Republic of China. FAU - Zhou, Guofeng AU - Zhou G AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. FAU - Zheng, Chuansheng AU - Zheng C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. LA - eng PT - Journal Article DEP - 20200210 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7020935 OTO - NOTNLM OT - CalliSpheres microspheres OT - chemoembolization OT - hepatocellular carcinoma OT - predictive factor OT - survival OT - treatment response COIS- The authors report no conflicts of interest in this work. EDAT- 2020/02/28 06:00 MHDA- 2020/02/28 06:01 PMCR- 2020/02/10 CRDT- 2020/02/28 06:00 PHST- 2018/09/13 00:00 [received] PHST- 2019/06/27 00:00 [accepted] PHST- 2020/02/28 06:00 [entrez] PHST- 2020/02/28 06:00 [pubmed] PHST- 2020/02/28 06:01 [medline] PHST- 2020/02/10 00:00 [pmc-release] AID - 187203 [pii] AID - 10.2147/CMAR.S187203 [doi] PST - epublish SO - Cancer Manag Res. 2020 Feb 10;12:941-956. doi: 10.2147/CMAR.S187203. eCollection 2020.